Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 228Neoplasm Metastasis 17Breast Neoplasms, Male 7Breast Diseases 7Neoplasms 6Carcinoma, Intraductal, Noninfiltrating 4Recurrence 3Obesity 3Breast Carcinoma In Situ 3Breast Cancer Metastatic 3Advanced Breast Cancer 3Neoplasms by Site 2Bulbo-Spinal Atrophy, X-Linked 2Arthralgia 2Vitamin D Deficiency 1Uterine Cervical Neoplasms 1Unilateral Breast Neoplasms 1Triple Negative Breast Neoplasms 1Thoracic Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sleep Wake Disorders 1Skin Diseases 1Sexual Dysfunctions, Psychological 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Primary Breast Cancer ER+ve 1Premenopausal Breast Cancer 1Post Menopausal Women With Early Breast Cancer 1Patient Acceptance of Health Care 1Pain 1

Interventions

trastuzumab biosimilar HLX02 1exemestane 1X-Rays 1Trastuzumab 1Taxes 1TVB-2640 1Specimen Handling 1Paclitaxel 1PF-05280014 1Ontruzant 1Ogivri 1Magnetic Resonance Spectroscopy 1Letrozole 1Fulvestrant 1Disulfides 1CT-P6 1Biopsy 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Breast Carcinoma × exemestane × Breast × Clear all
NCT03179904 2026-05-05

TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer

Mayo Clinic

Phase 2 Active not recruiting
17 enrolled 10 charts
Breast

Advanced Breast Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡